Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 12/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13559779 | 0.85 | AURKA (0.53) | MAPTRECQLAURKAKCNH2AURKB | |
| SCHEMBL20328913 | 0.81 | EGFR (0.52) | MAPTRECQLAURKAKCNH2AURKB | |
| SCHEMBL20353495 | 0.80 | MAPT (0.45) | MAPTRECQLAURKAKCNH2AURKB | |
| SCHEMBL18932537 | 0.80 | KDM4E (0.48) | MAPTRECQLAURKAKCNH2AURKB | |
| SCHEMBL2004023 | 0.78 | MAPT (0.46) | MAPTRECQLAURKAKCNH2AURKB | |
| SCHEMBL18705077 | 0.77 | MAPT (0.43) | MAPTRECQLAURKAKCNH2AURKB | |
| SCHEMBL20325477 | 0.77 | AURKA (0.45) | MAPTRECQLAURKAKCNH2AURKB | |
| SCHEMBL1087788 | 0.77 | AURKA (0.51) | MAPTRECQLAURKAKCNH2AURKB | |
| SCHEMBL23775544 | 0.76 | DRD2 (0.43) | KCNH2ALOX15ALDH1A1 | |
| SCHEMBL14375262 | 0.75 | KDM4E (0.51) | MAPTRECQLALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236122-B2 | Triterpene amine derivatives | DFH THERAPEUTICS (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | BET1, PGGT1B, NFATC1 | MAPT 1598/4885RECQL 3398/4885AURKA 2043/4885 |
| US-11236122-B2 | Triterpene amine derivatives | BET1, PGGT1B, NFATC1 | MAPT 1598/4885RECQL 3398/4885AURKA 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.